Serum Immunoglobulin G Is a Marker of Hidradenitis Suppurativa Disease Severity

• Published in: International journal of molecular sciences 2022-11, Vol.23 (22), p.13800
• Main Authors: Mintoff, Dillon, Borg, Isabella, Pace, Nikolai P
• Format: Article
• Language: English
• Subjects: Biomarkers; C-reactive protein; Cross-Sectional Studies; Dermatology; Erythrocyte sedimentation rate; Erythrocytes; Gender; Hematology; Hidradenitis Suppurativa - diagnosis; Humans; IgG antibody; Immunoglobulin G; Immunoglobulins; Inflammation; Leukocytes (neutrophilic); Lymphocytes; Metabolic syndrome; Pathophysiology; Plasma; Serology; Severity of Illness Index; Skin; Tumor necrosis factor-TNF
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232213800

Hidradenitis suppurativa (HS) is a chronic inflammatory condition of the skin that is brought about by autoinflammation and hyperkeratosis at the pilosebaceous unit. The clinical severity of HS can be measured using static (Hurley Severity Scoring (HSS)) and/or dynamic (International HS Severity Scoring System (IHS4)) severity scoring instruments. However, few clinically available serological parameters have been found to correlate with disease severity. In this study, we sought to investigate the role of serum immunoglobulin (Ig) G, M and A levels as biomarkers of disease severity and to compare them with other, more conventional inflammatory indices, such as the erythrocyte sedimentation rate, C-reactive protein, the neutrophil-lymphocyte ratio, the platelet-lymphocyte ratio and the systemic immune-inflammation index. In this cross-sectional study, patients were recruited from the only dermatology referral centre in Malta, Europe, and subjected to clinical examination and the assessment of inflammatory and immunologic parameters. Serum IgG, M and A levels were assessed using the Atellica NEPH 630 System (SIEMENS-Healthineers AF, Erlangen, Germany) nephelometric analyser. Serum IgG, M and A levels correlate with both dynamic and static HS severity scoring systems. Serum IgG behaves as a marker of severe HS disease as categorised by HSS and the IHS4. Our findings suggest that the serum IgG level can be used in the clinical setting as a biomarker of disease severity and, therefore, as an adjunct to clinical severity scoring.